ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?

被引：0
作者：
Hsu, Jingmei [1 ]
Kumar, Anita J. [1 ]
Carroll, Martin P. [1 ]
Frey, Noelle V. [1 ]
Shah, Nirav N. [1 ,2 ]
Jianhua, Zhao [3 ]
Hexner, Elizabeth O. [1 ]
Loren, Alison W. [1 ]
Mangan, James K. [1 ]
Perl, Alexander E. [1 ]
Porter, David [1 ]
Morrissette, Jennifer [3 ]
Luger, Selina M. [1 ]
机构：
[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Hosp Univ Penn, Philadelphia, PA 19104 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] ASXL1 mutations in idiopathic cytopenias: determined significance?
    Galvez, Carlos
    Stein, Brady L.
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (03) : 568 - 570
  • [32] PROGNOSTIC SIGNIFICANT OF ASXL1 MUTATIONS IN MYELODYSPLASTIC SYNDROMES
    Wang, S. Y.
    Lin, Y.
    Zheng, Y.
    Wang, Z. C.
    [J]. HAEMATOLOGICA, 2016, 101 : 501 - 501
  • [33] Prognostic Impact of ASXL1 Mutations in MDS and CMML
    Sallman, David
    Padron, Eric
    Vaupel, Christine
    Cluzeau, Thomas
    Al Ali, Najla H.
    Lancet, Jeffrey E.
    Hall, Jeff
    List, Alan F.
    Komrokji, Rami S.
    [J]. BLOOD, 2015, 126 (23)
  • [34] ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
    Metzeler, Klaus H.
    Becker, Heiko
    Maharry, Kati
    Radmacher, Michael D.
    Kohlschmidt, Jessica
    Mrozek, Krzysztof
    Nicolet, Deedra
    Whitman, Susan P.
    Wu, Yue-Zhong
    Schwind, Sebastian
    Powell, Bayard L.
    Carter, Thomas H.
    Wetzler, Meir
    Moore, Joseph O.
    Kolitz, Jonathan E.
    Baer, Maria R.
    Carroll, Andrew J.
    Larson, Richard A.
    Caligiuri, Michael A.
    Marcucci, Guido
    Bloomfield, Clara D.
    [J]. BLOOD, 2011, 118 (26) : 6920 - 6929
  • [35] In AML Secondary to MDS NPM1 Mutations Are Late Events, Less Frequent, and Associated with a Different Pattern of Molecular Mutations Than in De Novo AML
    Schnittger, Susanne
    Haferlach, Claudia
    Nadarajah, Niroshan
    Alpermann, Tamara
    Meggendorfer, Manja
    Perglerova, Karolina
    Kern, Wolfgang
    Haferlach, Torsten
    [J]. BLOOD, 2014, 124 (21)
  • [36] STAG2-mutated AML patients: ASXL1 cohesin binding motif status and mutation landscape.
    Scarpa, Frank J.
    Paul, Madhuri
    Wolfson, Wendy A.
    Weiss, Lawrence M.
    Funari, Vincent Anthony
    Blocker, Forrest
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] ASXL1 Mutations Associated with Cytogenetic Findings in DE NOVO and Secondary Acute Myeloid Leukemia
    Kakosaiou, K.
    Daraki, A.
    Apostolou, P.
    Zachaki, S.
    Pagoni, M.
    Sambani, C.
    Dimitriadis, G.
    Papa, V.
    Manola, K. N.
    [J]. ANNALS OF HEMATOLOGY, 2015, 94 : S80 - S80
  • [38] ASXL1 Mutations Associated with Cytogenetic Findings in DE NOVO and Secondary Acute Myeloid Leukemia
    Kakosaiou, K.
    Daraki, A.
    Apostolou, P.
    Zachaki, S.
    Pagoni, M.
    Sambani, C.
    Dimitriadis, G.
    Papa, V.
    Manola, K. N.
    [J]. ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 80 - 80
  • [39] ASXL1 mutations in myelodysplatic syndromes and their cooperation with additional gene mutations in the progression to secondary acute myeloid leukemia
    Chang, H.
    Shih, Y. S.
    Lin, T. H.
    Huang, Y. H.
    Liang, D. C.
    Liang, S. T.
    Kuo, M. C.
    Wang, P. N.
    Wu, J. H.
    Shih, L. Y.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S38 - S38
  • [40] RUNX1-MUTATED AML SHOW A HIGH FREQUENCY OF TRISOMY 8 AND TRISOMY 13 AND ARE ASSOCIATED WITH MUTATIONS IN ASXL1 AND COMPONENTS OF THE RNA-SPLICING MACHINERY
    Stengel, A.
    Kern, W.
    Meggendorfer, M.
    Perglerova, K.
    Haferlach, T.
    Haferlach, C.
    [J]. HAEMATOLOGICA, 2016, 101 : 362 - 362
12345